Pacira BioSciences' Current Deferred Revenue fell 8285.71% to $102000.0 in Q4 2017 from the same period last year, while for Dec 2017 it was $102000.0, marking a year-over-year decrease of 8285.71%. This contributed to the annual value of $102000.0 for FY2017, which is 8285.71% down from last year.
Pacira BioSciences' Current Deferred Revenue amounted to $102000.0 in Q4 2017, which was down 8285.71% from $520000.0 recorded in Q1 2017.
In the past 5 years, Pacira BioSciences' Current Deferred Revenue ranged from a high of $1.4 million in Q2 2014 and a low of $102000.0 during Q4 2017
Moreover, its 5-year median value for Current Deferred Revenue was $1.0 million (2013), whereas its average is $1.1 million.
Its Current Deferred Revenue has fluctuated over the past 5 years, first plummeted by 8655.79% in 2013, then soared by 4670.78% in 2014.
Over the past 5 years, Pacira BioSciences' Current Deferred Revenue (Quarter) stood at $1.0 million in 2013, then surged by 41.47% to $1.4 million in 2014, then changed by 0.0% to $1.4 million in 2015, then crashed by 58.27% to $595000.0 in 2016, then crashed by 82.86% to $102000.0 in 2017.
Its Current Deferred Revenue stands at $102000.0 for Q4 2017, versus $520000.0 for Q1 2017 and $595000.0 for Q4 2016.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value